What the FDA labels say about taking them together
Cabotegravir and rifampin
Cabotegravir's FDA label of April 11, 2025 names rifampin in its contraindications section, and rifampin's label names cabotegravir too. The cabotegravir label: “Coadministration is contraindicated with VOCABRIA due to potential for loss of efficacy and development of resistance.”
Check it at the source: the cabotegravir FDA label on DailyMed (effective April 11, 2025, ViiV Healthcare Company); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the cabotegravir label say about rifampin?
Cabotegravir label, contraindicationsCarbamazepine, oxcarbazepine, phenobarbital, phenytoin o Antimycobacterials: Rifampin, rifapentine Unknown or positive HIV-1 status.
Cabotegravir label, drug interactionsConcomitant Drug Class/Drug Name: Antimycobacterials: Rifampin Rifapentine; Effect on Concentration: ↓Cabotegravir; Clinical Comment: Coadministration is contraindicated with APRETUDE due to potential for significant decreases in plasma concentration of APRETUDE.
Vocabria label (ViiV Healthcare Company, April 11, 2025), contraindicationsCarbamazepine, oxcarbazepine, phenobarbital, phenytoin o Antimycobacterials: Rifampin, rifapentine Prior to initiation of VOCABRIA, note that use of CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) with rifabutin is contraindicated.
Vocabria label (ViiV Healthcare Company, April 11, 2025), drug interactionsConcomitant Drug Class/Drug Name: Antimycobacterials a: Rifampin Rifapentine; Effect on Concentration: ↓Cabotegravir; Clinical Comment: Coadministration is contraindicated with VOCABRIA due to potential for loss of efficacy and development of resistance [see Contraindications ()].
Source: FDA drug label (Vocabria, NDA212887), ViiV Healthcare Company, effective April 11, 2025 (SPL set 66d450fb-cca4-476c-b0c7-c0730e3e4cf3), via openFDA
Source: FDA drug label (Apretude), ViiV Healthcare Company, effective April 11, 2025 (SPL set 4338428e-43d4-4e02-ac9d-bd98e738a7da), via openFDA; the full label on DailyMed
What does the rifampin label say about cabotegravir?
Rifampin label, contraindicationsRifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir and lenacapavir (see prescribing information for SUNLENCA) due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in decreased antiviral efficacy and/or development of viral resistance. (See PRECAUTIONS, Drug Interactions ).
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cabotegravir | Rifampin | |
|---|---|---|
| Labeled for | HIV | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once